Transaction DateRecipientSharesTypePriceValue
31st December 2020Gary Sender32Payment by withholding$2.42$77.44
17th December 2020Charles A Jr Rowland10,909Open or private sale$117.82$1,285,298.38
17th December 2020Charles A Jr Rowland10,909Exercise of derivative$19.53$213,052.77
7th December 2020Carrie L. Bourdow132,934Payment by withholding$2.27$301,760.18
30th November 2020Robert Crotty368Payment by withholding$0.43$157.14
30th November 2020Steven P. Gelone628Payment by withholding$0.43$268.16
30th November 2020Jennifer Schranz301Payment by withholding$0.43$128.53
30th November 2020Theodore R Schroeder1,211Payment by withholding$0.43$517.10
30th November 2020Gary Sender312Payment by withholding$0.43$133.22
3rd November 2020Charles A Jr Rowland694Open or private sale$95.97$66,603.18
Nabriva Therapeutics Plc
Nabriva Therapeutics Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company. It engages in the research and development of novel antibiotics to treat serious infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Ticker: NBRV
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1641640
Employees: 162
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $50 M (-42%)
Inventory, Net: $5 M (661%)
Assets, Current: $62 M (-31%)
Property, Plant and Equipment, Net: $2 M (-12%)
Assets: $65 M (-30%)
Accounts Payable, Current: $3 M (-43%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $11 M (-33%)
Long-term Debt, Excluding Current Maturities: $7 M (-78%)
Other Liabilities, Noncurrent: $2 M (24%)
Liabilities: $21 M (-61%)
Common Stock, Value, Issued: $1 M (51%)
Common Stock, Shares, Issued: $143 M (51%)
Additional Paid in Capital, Common Stock: $558 M (8%)
Retained Earnings (Accumulated Deficit): $515 M (8%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $27 Th (0%)
Stockholders' Equity (Parent): $44 M (0%)
Liabilities and Equity: $65 M (-30%)
Revenue: $487 Th (0%)
Cost of Revenue: $368 Th (-2%)
Research and Development: $6 M (-43%)
Operating Income/Loss: $14 M (-58%)
Provision for income taxes: $119 Th (19%)